ArticleLipids in health and disease2026
Plasma lipidomic profiling reveals the potential protective role of lipids in cerebral small vessel disease.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLimited understanding of the pathophysiology of cerebral small vessel disease (CSVD) has hampered the development of effective treatments. Lipidomics offers a promising approach for identifying molecular signatures, clarifying underlying pathogenic mechanisms, and predicting disease severity and progression.
methodsA total of 1161 participants with lipidomic data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database were included and matched to each neuroimaging marker of CSVD separately, including cerebral microbleeds (CMBs, n = 578), white matter hyperintensities (WMHs, n = 650), lacunes (n = 1125), and CSVD burden (n = 546). Three complementary classification strategies (class-based grouping, model-based clustering, and individual lipid species) were employed to investigate lipid signatures across various CSVD markers. A multimodel regression framework followed by a series of sensitivity analyses was used to further identify lipid species showing robust associations with each CSVD marker.
resultsA total of 46 lipid classes, 25 lipid clusters, and 749 lipid species were quantified. Individuals with CSVD presented broadly reduced plasma lipid levels, particularly those of glycerophospholipids and glycerolipids. A multimodel regression framework initially screened 32 lipid species associated with the presence or progression of CSVD. Subsequent sensitivity analyses narrowed these to 13 robust species, including phosphatidylcholine, triacylglycerol, phosphatidylethanolamine, alkenyl-phosphatidylethanolamine, and sphingomyelin. Among these, elevated levels of PC(36:4)[+ OH] and TG(56:6)[NL-20:4] were associated with lower odds of CMBs and reduced WMH volumes, respectively, whereas higher levels of PC(15:0_20:3) and SM(d16:1/19:0) were linked to lower odds of lacunes, with all associations consistently observed across baseline, year 1, and year 2.
conclusionThis study revealed dysregulated lipid metabolism across distinct magnetic resonance imaging phenotypes of CSVD and revealed multiple lipid species that are consistently associated with the presence and progression of these phenotypes, underscoring the potential of lipidomics for the earlier identification and prevention of CSVD and informing future diagnostic development and mechanistic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.